Correlation Between Roche Holding and GlaxoSmithKline PLC
Can any of the company-specific risk be diversified away by investing in both Roche Holding and GlaxoSmithKline PLC at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Roche Holding and GlaxoSmithKline PLC into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Roche Holding Ltd and GlaxoSmithKline PLC ADR, you can compare the effects of market volatilities on Roche Holding and GlaxoSmithKline PLC and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Roche Holding with a short position of GlaxoSmithKline PLC. Check out your portfolio center. Please also check ongoing floating volatility patterns of Roche Holding and GlaxoSmithKline PLC.
Diversification Opportunities for Roche Holding and GlaxoSmithKline PLC
0.77 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Roche and GlaxoSmithKline is 0.77. Overlapping area represents the amount of risk that can be diversified away by holding Roche Holding Ltd and GlaxoSmithKline PLC ADR in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on GlaxoSmithKline PLC ADR and Roche Holding is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Roche Holding Ltd are associated (or correlated) with GlaxoSmithKline PLC. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of GlaxoSmithKline PLC ADR has no effect on the direction of Roche Holding i.e., Roche Holding and GlaxoSmithKline PLC go up and down completely randomly.
Pair Corralation between Roche Holding and GlaxoSmithKline PLC
Assuming the 90 days horizon Roche Holding Ltd is expected to generate 0.95 times more return on investment than GlaxoSmithKline PLC. However, Roche Holding Ltd is 1.05 times less risky than GlaxoSmithKline PLC. It trades about -0.14 of its potential returns per unit of risk. GlaxoSmithKline PLC ADR is currently generating about -0.24 per unit of risk. If you would invest 4,116 in Roche Holding Ltd on September 2, 2024 and sell it today you would lose (500.00) from holding Roche Holding Ltd or give up 12.15% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Significant |
Accuracy | 100.0% |
Values | Daily Returns |
Roche Holding Ltd vs. GlaxoSmithKline PLC ADR
Performance |
Timeline |
Roche Holding |
GlaxoSmithKline PLC ADR |
Roche Holding and GlaxoSmithKline PLC Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Roche Holding and GlaxoSmithKline PLC
The main advantage of trading using opposite Roche Holding and GlaxoSmithKline PLC positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Roche Holding position performs unexpectedly, GlaxoSmithKline PLC can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GlaxoSmithKline PLC will offset losses from the drop in GlaxoSmithKline PLC's long position.Roche Holding vs. Brainsway | Roche Holding vs. Venus Concept | Roche Holding vs. Tactile Systems Technology | Roche Holding vs. Icecure Medical |
GlaxoSmithKline PLC vs. Novartis AG ADR | GlaxoSmithKline PLC vs. AstraZeneca PLC ADR | GlaxoSmithKline PLC vs. Roche Holding Ltd | GlaxoSmithKline PLC vs. Bristol Myers Squibb |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |